share_log

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Supernus Pharmaceuticals, Inc. (纳斯达克:SUPN) 表现强劲,但基本面似乎有些混杂:股票是否有明确的方向?
Simply Wall St ·  04:33

Supernus Pharmaceuticals (NASDAQ:SUPN) has had a great run on the share market with its stock up by a significant 16% over the last three months. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current share price momentum can be maintained. In this article, we decided to focus on Supernus Pharmaceuticals' ROE.

Supernus Pharmicals(纳斯达克股票代码:SUPN)在股市上表现良好,其股票在过去三个月中大幅上涨了16%。但是该公司的关键财务指标似乎各不相同,这使我们质疑该公司目前的股价势头是否可以维持。在本文中,我们决定重点关注Supernus Pharmaceuticals的投资回报率。

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.

股本回报率或投资回报率是用于评估公司管理层利用公司资本效率的关键衡量标准。简而言之,它衡量公司相对于股东权益的盈利能力。

How Do You Calculate Return On Equity?

你如何计算股本回报率?

The formula for return on equity is:

股本回报率的公式是:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回报率 = 净利润(来自持续经营)÷ 股东权益

So, based on the above formula, the ROE for Supernus Pharmaceuticals is:

因此,根据上述公式,Supernus Pharmicals的投资回报率为:

5.9% = US$60m ÷ US$1.0b (Based on the trailing twelve months to September 2024).

5.9% = 6000万美元 ÷ 10亿美元(基于截至2024年9月的过去十二个月)。

The 'return' is the income the business earned over the last year. That means that for every $1 worth of shareholders' equity, the company generated $0.06 in profit.

“回报” 是企业在过去一年中获得的收入。这意味着,每获得价值1美元的股东权益,该公司就会产生0.06美元的利润。

Why Is ROE Important For Earnings Growth?

为什么投资回报率对收益增长很重要?

So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

到目前为止,我们已经了解到,投资回报率是衡量公司盈利能力的指标。然后,根据公司对这些利润进行再投资或 “保留” 的金额及其有效性,我们就能评估公司的盈利增长潜力。假设其他一切都保持不变,那么与不一定具有这些特征的公司相比,投资回报率和利润保留率越高,公司的增长率就越高。

Supernus Pharmaceuticals' Earnings Growth And 5.9% ROE

Supernus Pharmaceuticals的收益增长和5.9%的投资回报率

At first glance, Supernus Pharmaceuticals' ROE doesn't look very promising. Next, when compared to the average industry ROE of 21%, the company's ROE leaves us feeling even less enthusiastic. For this reason, Supernus Pharmaceuticals' five year net income decline of 35% is not surprising given its lower ROE. However, there could also be other factors causing the earnings to decline. For example, it is possible that the business has allocated capital poorly or that the company has a very high payout ratio.

乍一看,Supernus Pharmaceuticals的投资回报率看起来并不十分乐观。接下来,与21%的行业平均投资回报率相比,该公司的投资回报率使我们感到不那么热情。出于这个原因,鉴于投资回报率较低,Supernus Pharmaceuticals的五年净收入下降了35%,这并不奇怪。但是,可能还有其他因素导致收益下降。例如,企业的资本分配可能不力,或者公司的派息率很高。

However, when we compared Supernus Pharmaceuticals' growth with the industry we found that while the company's earnings have been shrinking, the industry has seen an earnings growth of 1.2% in the same period. This is quite worrisome.

但是,当我们将Supernus Pharmaceuticals的增长与该行业的增长进行比较时,我们发现,尽管该公司的收益一直在萎缩,但该行业同期的收益增长了1.2%。这非常令人担忧。

big
NasdaqGM:SUPN Past Earnings Growth December 14th 2024
纳斯达克通用汽车公司:SUPN过去的收益增长 2024年12月14日

Earnings growth is a huge factor in stock valuation. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Supernus Pharmaceuticals fairly valued compared to other companies? These 3 valuation measures might help you decide.

收益增长是股票估值的重要因素。投资者接下来需要确定的是,预期的收益增长或缺乏收益是否已经包含在股价中。通过这样做,他们将知道股票是走向清澈的蓝色海水还是沼泽水域在等着呢。与其他公司相比,Supernus Pharmicals的估值是否合理?这3种估值指标可能会帮助您做出决定。

Is Supernus Pharmaceuticals Efficiently Re-investing Its Profits?

Supernus Pharmicals 是否有效地将其利润再投资?

Supernus Pharmaceuticals doesn't pay any regular dividends, meaning that potentially all of its profits are being reinvested in the business, which doesn't explain why the company's earnings have shrunk if it is retaining all of its profits. So there could be some other explanations in that regard. For instance, the company's business may be deteriorating.

Supernus Pharmicals不支付任何定期股息,这意味着其所有利润都可能被再投资于该业务,这并不能解释为什么如果该公司保留所有利润,其收益就会萎缩。因此,在这方面可能还有其他解释。例如,该公司的业务可能正在恶化。

Conclusion

结论

In total, we're a bit ambivalent about Supernus Pharmaceuticals' performance. Even though it appears to be retaining most of its profits, given the low ROE, investors may not be benefitting from all that reinvestment after all. The low earnings growth suggests our theory correct. Having said that, looking at current analyst estimates, we found that the company's earnings growth rate is expected to see a huge improvement. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

总的来说,我们对Supernus Pharmaceuticals的表现有点矛盾。尽管鉴于投资回报率低,它似乎保留了大部分利润,但投资者毕竟可能无法从所有这些再投资中受益。低收入增长表明我们的理论是正确的。话虽如此,从分析师目前的估计来看,我们发现该公司的收益增长率预计将出现巨大改善。这些分析师的预期是基于对该行业的广泛预期,还是基于公司的基本面?点击此处进入我们分析师对公司的预测页面。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?担心内容吗?直接联系我们。或者,发送电子邮件给编辑组(网址为)simplywallst.com。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发